Literature DB >> 12792488

Penetrating keratoplasty and keratolimbal allograft transplantation for corneal perforations associated with the ectodermal dysplasia syndrome.

Nicole J Anderson1, David R Hardten, Tina M McCarty.   

Abstract

PURPOSE: To report two patients with ectodermal dysplasia-associated keratopathy treated with keratolimbal allograft transplantation and penetrating keratoplasty.
METHODS: Two patients with ectodermal dysplasia suffered multiple corneal perforations. In both patients, keratolimbal allograft transplantation was performed along with penetrating keratoplasty. Histopathology of the corneal buttons was obtained.
RESULTS: Histopathologic examination showed chronic inflammation with thin, irregular epithelium, loss of stromal tissue, and thin or absent Bowman's membrane. Both patients had multiple contributing factors predisposing them to corneal perforations including an inherent ectodermal defect, trichiasis, poor tear film, and limbal stem cell deficiency.
CONCLUSIONS: Patients with keratopathy and corneal perforations associated with the ectodermal dysplasia syndrome has a poor prognosis. Keratolimbal allograft transplantation may have a role in the treatment of this disease. Longer follow-up and additional case reports will determine whether this technique confers a better prognosis than keratoplasty alone.

Entities:  

Mesh:

Year:  2003        PMID: 12792488     DOI: 10.1097/00003226-200305000-00022

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  3 in total

Review 1.  Graft failure: II. Ocular surface complications.

Authors:  Samar A Al-Swailem
Journal:  Int Ophthalmol       Date:  2008-06       Impact factor: 2.031

2.  Limbal stem cells in review.

Authors:  Marzieh Ebrahimi; Ehsan Taghi-Abadi; Hossein Baharvand
Journal:  J Ophthalmic Vis Res       Date:  2009-01

3.  Long-Term Outcomes of Allogeneic Ocular Surface Reconstruction: Keratolimbal Allograft (KLAL) Followed by Penetrating Keratoplasty (PK).

Authors:  Katarzyna Krysik; Dariusz Dobrowolski; Dorota Tarnawska; Edward Wylegala; Anita Lyssek-Boroń
Journal:  J Ophthalmol       Date:  2020-04-14       Impact factor: 1.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.